Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772)
😃Good
Catalog No. TMAY-00148F
Alias tumor necrosis factor receptor superfamily, member 9, Ly63, ILA, CDw137, Cd137, AI325004, AA408498, A930040I11Rik, 4-1BB
Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) is a FITC-conjugated Rabbit antibody targeting 4-1BB/CD137/TNFRSF9. Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) can be used in FCM.
Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772)
Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772)
😃Good
Catalog No. TMAY-00148FAlias tumor necrosis factor receptor superfamily, member 9, Ly63, ILA, CDw137, Cd137, AI325004, AA408498, A930040I11Rik, 4-1BB
Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) is a FITC-conjugated Rabbit antibody targeting 4-1BB/CD137/TNFRSF9. Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 T | $105 | 7-10 days | 7-10 days | |
| 100 T | $258 | 7-10 days | 7-10 days |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) is a FITC-conjugated Rabbit antibody targeting 4-1BB/CD137/TNFRSF9. Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) can be used in FCM. |
| Synonyms | tumor necrosis factor receptor superfamily, member 9, Ly63, ILA, CDw137, Cd137, AI325004, AA408498, A930040I11Rik, 4-1BB |
| Ig Type | Rabbit IgG |
| Clone | 1B772 |
| Reactivity | Human |
| Specificity | Human 4-1BB/CD137 |
| Verified Activity | Flow cytometric analysis of Human CD137 expression on PHA-activated human whole blood lymphocytes. Cells were stained with FITC-conjugated anti-Human CD137. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
| Application | |
| Recommended Dose | 10 μl/Test, 0.1 mg/ml |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human CD137 (rh CD137; TMPY-01743; NP_001552.2; Met1-Gln186) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Research Background | CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+and CD8+T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Conjucates | FITC |
| Others Formats | Unconjugated/APC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human CD137 Protein (TMPY-01743) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) | purchase Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) | Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772) cost | order Anti-4-1BB/CD137/TNFRSF9 Antibody-FITC (1B772)
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.